Rejoint (www.rejoint.life.com) has been incorporated in 2016 by industry experts, supported by orthopedic KOL’s, with the mission of developing a revolutionary concept for “tailor made” knee prosthesis. Medeor invested in Rejoint at a seed stage and followed subsequent capital increases.
Rejoint business model is a combination of patient’s anatomy data collection, procedure planning, tailor-made knee prosthesis manufacturing (3-D technology), intra-operative robotic surgical assistance and post-surgery recovery monitoring. As a result, knee surgery according to Rejoint procedure provide a better patient outcome (less pain, less blood loss, faster recovery) and shorter surgical room occupancy.
Rejoint obtained the CE mark in 2020. Covid pandemic delayed all “elective” surgical procedures (including knee replacement surgery) and only in second half 2021 Rejoint has been able to initiate and expand commercial sales.